Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HCWB with free AI briefings, catalyst countdowns, and dilution alerts.

HCWB · HCW Biologics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$955,458 Cash on Hand
0.9mo Cash Runway
Follow HCWB by email Get an email when HCWB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HCWB, unsubscribe in one click. Privacy

📣 What HCWB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Bifunctional TGF-beta Antagonist/IL-15 Protein… Ovarian Cancer Phase 2 · NCT05145569 Withdrawn

Also used in these trials (approved or third-party drugs, not HCWB's own candidates): Paclitaxel, HCW9302, an IL-2 fusion protein.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HCWB holds $955,458 in cash and short-term investments (as of Sep 30, 2026) and burns about $3.3M/quarter from operations, an estimated runway of 0.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 62 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HCWB files for a raise →

👥 Who Owns HCWB

Insiders 11.2% Other 5%+ holders 16% Institutions (15 holders) 8.4% Public and other holders 64.4%
HolderTypeShares% of sharesAs of
Hing C. Wong, Ph.D. 5%+ holder (13D) 501,911 15.98% 2025-05-15
Armistice Capital, LLC Institution (13G, 5%+) 248,204 7.90% 2026-09-30
Hing C Wong
Chief Executive Officer, Director, 10% o · +164,360 options
Insider 125,845 4.01% 2026-07-29
Peter Rhode
Officer · +58,854 options
Insider 77,500 2.47% 2023-12-11
Rebecca Byam
Chief Financial Officer · +22,697 options
Insider 57,245 1.82% 2026-05-22
Scott T Garrett
Director · +195,820 options
Insider 41,644 1.33% 2026-07-29
Lisa M. Giles
Director
Insider 35,815 1.14% 2024-02-20
Lee Flowers
SVP of Business Development · +481 options
Insider 8,691 0.28% 2026-07-29
Gary M Winer
Director · +13,654 options
Insider 4,075 0.13% 2025-05-16
Rick S. Greene
Director · +12,981 options
Insider 2,066 0.07% 2025-05-07

Share count 3,139,938 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HCWB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HCWB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.